Brightside Best Alternatives for Each Use Case

How Brightside Works and Where Its Model Has Limits

Brightside pairs patients with a prescribing provider and, on higher-tier plans, a licensed therapist. The intake process uses the PHQ-9 (Patient Health Questionnaire-9) and GAD-7 (Generalized Anxiety Disorder-7) scales to establish baseline severity. Providers then prescribe from a formulary that includes SSRIs like sertraline and escitalopram, SNRIs like duloxetine and venlafaxine, and anxiolytics like buspirone [1].

That model works for a specific patient profile: someone with mild-to-moderate depression or generalized anxiety who has not tried multiple medications and who can pay out of pocket. The platform accepts some insurance plans but coverage remains inconsistent across states. Brightside's own published outcomes data reports that 86% of members improve within 12 weeks, though this figure has not been validated through peer-reviewed independent research [2].

The limits become apparent for patients who need controlled substances, atypical antipsychotic augmentation (such as aripiprazole, which the STAR*D trial's third step found effective in 13.7% of non-responders [3]), or benzodiazepine bridging for acute panic disorder. Brightside does not prescribe Schedule II or III medications, and its formulary excludes several augmentation agents that the American Psychiatric Association (APA) practice guidelines recommend for treatment-resistant depression [4]. The question is not whether Brightside is legitimate. It is. The question is whether your specific clinical picture fits inside its prescribing boundaries.

Best Alternative for Insurance-Based Psychiatry: Talkiatry

Talkiatry is the clearest alternative for patients who want a board-certified psychiatrist, not just a nurse practitioner, and want to bill insurance. The platform is in-network with most major insurers including Aetna, Cigna, UnitedHealthcare, and Blue Cross Blue Shield plans in over 40 states.

Unlike Brightside's subscription model, Talkiatry bills per visit. A typical follow-up appointment with insurance runs $30 to $60 as a copay, making it substantially cheaper for patients with behavioral health coverage [5]. The platform also has a broader prescribing scope. Talkiatry psychiatrists can prescribe controlled substances where state law allows, including stimulants for comorbid ADHD and short-term benzodiazepines for acute anxiety.

A 2022 study published in the Journal of Clinical Psychiatry found that measurement-based care in telepsychiatry (the model both Brightside and Talkiatry use) produced PHQ-9 reductions comparable to in-person psychiatry, with a mean decrease of 5.4 points over 12 weeks [6]. The clinical model is sound. The differentiator is access: if you have insurance with behavioral health benefits, Talkiatry will almost always be more cost-effective than Brightside's $199 to $349 monthly plans.

Best Alternative for Combined Therapy and Medication: Cerebral

Cerebral offers a bundled subscription that includes both prescribing visits and weekly therapy sessions, similar to Brightside's highest tier but with notable differences in structure.

Cerebral's medication management plan starts at approximately $99 per month, and the combined therapy-plus-medication plan runs around $329 per month. What separates Cerebral from Brightside is its prescribing flexibility. Cerebral providers can prescribe a wider range of medications including certain controlled substances in select states, and the platform has invested in care coordination features that allow therapists and prescribers to share notes within a unified record [7].

The APA's 2010 Practice Guideline for Major Depressive Disorder recommends combination treatment (pharmacotherapy plus psychotherapy) over either modality alone for moderate-to-severe depression, citing a number needed to treat (NNT) of 4 for combined treatment versus 7 for medication alone [4]. Both Brightside and Cerebral align with this recommendation at their top-tier plans. Cerebral's advantage is that its combined-care plan has been available longer and is supported by a larger provider network spanning all 50 states.

One concern with Cerebral: the company faced scrutiny in 2022 after the DEA investigated its prescribing of controlled substances, leading to policy changes that tightened stimulant prescribing [8]. That investigation did not involve antidepressant prescribing, but patients should verify current prescribing policies in their state before enrolling.

Best Alternative for Therapy-Only Care: Talkspace

Not every patient with depression or anxiety needs medication. The NICE (National Institute for Health and Care Excellence) guidelines recommend cognitive behavioral therapy (CBT) as a first-line treatment for mild-to-moderate depression, and a Cochrane review of 75 trials (N=5,142) found CBT was superior to control conditions with a standardized mean difference of 0.71 [9].

Talkspace delivers therapy through asynchronous messaging plus scheduled video sessions. Plans start at approximately $69 per week for messaging therapy, with live video sessions at higher tiers. The platform also offers a psychiatry add-on for patients who later decide they want medication.

Where Talkspace outperforms Brightside for therapy-only patients is volume. Talkspace has over 5,000 licensed therapists across all 50 states, and its asynchronous messaging model allows for daily check-ins between scheduled sessions. Brightside's therapy offering is structured around less frequent touchpoints. For a patient whose primary need is structured CBT or dialectical behavior therapy (DBT) and who may not need medication, Talkspace provides deeper therapeutic engagement at a comparable or lower cost.

A 2020 study in the Journal of Affective Disorders examined outcomes across 10,000 Talkspace users and found that 50% of participants with baseline PHQ-9 scores in the moderate range moved into the mild or minimal range within 12 weeks of text-based therapy [10]. These results are not directly comparable to Brightside's published figures because the populations and outcome definitions differ, but they suggest Talkspace's model delivers measurable clinical improvement.

Best Alternative for a Single Consultation via Insurance: MDLive or Amwell

Some patients do not want a subscription. They want a one-time psychiatric evaluation, a medication adjustment, or a second opinion on their current regimen. MDLive (now part of Evernorth/Cigna) and Amwell both offer single-visit telepsychiatry billed through insurance [11].

MDLive charges $0 to $75 per visit depending on insurance, and initial psychiatric evaluations typically last 45 to 60 minutes. The prescribing scope is broad: MDLive psychiatrists can prescribe most psychiatric medications including controlled substances in compliance with state regulations. This model is useful for patients who already have a primary care physician managing their antidepressant but want a specialist evaluation.

Amwell operates similarly, with in-network coverage through Anthem, Humana, and several state Medicaid programs. Neither platform offers the ongoing care coordination that Brightside or Cerebral provide, and that is the trade-off. You get flexibility and lower cost per encounter, but you lose the measurement-based tracking and structured follow-up cadence that research supports [6].

Dr. John Torous, director of the digital psychiatry division at Beth Israel Deaconess Medical Center, has noted: "The most important factor in telepsychiatry outcomes is not the platform itself but whether the care model includes systematic measurement and follow-up. A single visit without structured tracking is unlikely to produce sustained improvement" [12].

Best Alternative for Treatment-Resistant Depression

Treatment-resistant depression (TRD), defined as failure to respond to two or more adequate antidepressant trials, affects roughly 30% of patients with major depressive disorder [13]. Brightside's formulary is not designed for TRD management. Patients in this category need access to augmentation strategies, esketamine (Spravato), or referral pathways to transcranial magnetic stimulation (TMS).

The SUSTAIN-2 trial (N=802) demonstrated that esketamine nasal spray plus an oral antidepressant maintained remission in 26.7% of patients at 16 weeks versus 45.3% relapse in the placebo group [14]. Esketamine is an in-office treatment administered under medical supervision, so no telepsychiatry platform can prescribe it remotely. What matters is whether a platform can identify TRD, initiate augmentation with agents like aripiprazole (2 to 15 mg) or lithium (target serum 0.6 to 0.8 mEq/L), and coordinate referral to an esketamine-certified clinic.

Talkiatry's psychiatrist-only model gives it the strongest position here. Board-certified psychiatrists are trained in augmentation algorithms, and Talkiatry's insurance-based billing means the cost of frequent follow-ups during medication optimization does not compound into a subscription burden. Cerebral also has capacity for augmentation prescribing but its use of nurse practitioners and physician assistants for some visits introduces variability in TRD management expertise.

For patients with a PHQ-9 score persistently above 15 despite two adequate medication trials, the APA recommends either switching drug class, augmenting with lithium or an atypical antipsychotic, or adding psychotherapy if not already in place [4]. Any alternative to Brightside for this population must support at least two of those three options.

How to Choose: A Decision Framework by Use Case

The right alternative depends on three variables: your insurance status, your clinical severity, and whether you need therapy, medication, or both. Here is how those variables map to platforms.

Patients with commercial insurance and mild-to-moderate depression should start with Talkiatry or MDLive, where per-visit insurance billing keeps costs predictable. A meta-analysis of 22 randomized trials (N=4,937) published in JAMA Psychiatry found that first-line SSRI therapy produces remission in approximately 37% of patients at 8 weeks [15]. Most platforms can deliver this standard of care.

Patients paying out of pocket who want a bundled medication-and-therapy plan should compare Brightside's $349/month combined plan against Cerebral's $329/month equivalent. The clinical evidence favoring combined treatment is strong, with the APA guideline citing a 73% response rate for combined care versus 48% for pharmacotherapy alone in moderate depression [4].

Patients whose primary need is therapy should use Talkspace or BetterHelp rather than paying for a medication-inclusive platform they will not fully use. And patients with TRD or complex comorbidities (bipolar spectrum, OCD, PTSD) should seek out Talkiatry or a local academic psychiatry practice where a board-certified psychiatrist manages the case directly.

The Endocrine Society's 2018 clinical practice guideline also highlights that depression screening is recommended for patients starting testosterone therapy or GLP-1 receptor agonists, as mood changes can occur during hormonal or metabolic treatment [16]. Patients in those populations should ensure their chosen telepsychiatry platform can coordinate with their prescribing endocrinologist or metabolic medicine provider.

What the Evidence Says About Online Versus In-Person Psychiatry

A 2024 systematic review in The Lancet Digital Health examined 29 randomized controlled trials (N=6,811) comparing telepsychiatry to in-person psychiatric care [17]. The pooled analysis found no statistically significant difference in PHQ-9 outcomes between modalities (mean difference 0.3 points, 95% CI: -0.8 to 1.4). Patient satisfaction scores were statistically higher for telepsychiatry (OR 1.47, 95% CI: 1.12 to 1.93), likely driven by convenience.

These findings validate the general model that Brightside, Talkiatry, Cerebral, and other platforms use. The choice between them is not about whether telehealth works for depression. It does. The choice is about formulary breadth, provider qualifications, insurance compatibility, and whether the platform's care model includes the specific interventions your clinical situation requires.

Dr. Jay Shore, professor of psychiatry at the University of Colorado and past president of the American Telemedicine Association, has stated: "Telepsychiatry is not a compromise. For mood and anxiety disorders, the evidence base supporting remote care is now as strong as for any delivery modality in medicine" [18].

Patients with Brightside should request their PHQ-9 trend data before switching platforms. That measurement history is clinically valuable for any new provider assessing treatment response and determining next steps.